United Therapeutics Corp. (UTHR) PT Raised to $245 at Jefferies

Jefferies analyst Eun Yang raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $245.00 (from $223.00) while maintaining a Buy rating.

The analyst commented, "Though FDA approval of Tyvaso DPI was cautiously anticipated, broad & clean approval for both indications without boxed warning for safety concerns is the best-case scenario outcome. This makes an ongoing patent litigation with LQDA for Tyvaso franchise no longer a concern given UTHR's first-to-market advantage & long-established presence in this therapeutic space. Highly profitable franchise with a clear path for strong growth
potential makes UTHR attractive."

You May Also Be Interested In

• Amrize Ltd (AMRZ) PT Raised to $43 at DA Davidson
• Bernstein SocGen Slashes Reddit (RDDT) Stock PT to $120
• Eli Lilly (LLY) PT Raised to $1,600 at RBC Capital After an 'Impressive Quarter'